

EQUITY RESEARCH REPORT | Report date: August 16, 2026 | Prices as of the close, August 14, 2026

Marvell Technology, Inc. (NASDAQ: MRVL)

Semiconductors • Data Infrastructure • Custom XPU, Optical DSP, Interconnect • Santa Clara, California

Price (Aug 14 close)	\$222.02	Prob-weighted fair value	\$202 (-9.1%)
Change since last report	+14.3% (from \$194.23)	Expected return, base case	-9.1%
Move off the July 29 low	+35.9% (from \$163.40)	EV (approx.)	\$205B (was \$179B)
FY27 non-GAAP P/E	~56x (was 49x)	EV / FY27 guided revenue	17.8x (was 15.5x)
FY28 non-GAAP P/E	~39x (was 34x)	ATR(14)	\$17.01 (7.7% of price)
FY27 revenue guide	~\$11.5B (+40%)	FY28 target	\$16.5B (+45%)
Next earnings	Aug 27, 2026 (11 days)	Consensus target	~\$244-257; Strong Buy

RECOMMENDATION

WATCHLIST

reaffirmed — unchanged
from July 26

Thesis in one line: The July report declined to buy at \$194.23 because the probability-weighted fair value of \$196 offered no compensation for a security with 99% realised volatility, and it named \$158–178 as the zone that would. That zone was reached three days later, on July 29, at an intraday low of \$162.90. The stock has since risen 35.9% off it on a genuinely good product cycle and a regulatory tailwind, and now trades 9.1% above a fair value that has itself moved up only modestly. The rating is unchanged and so is the score, but the reason has flipped: in July this was fairly valued with a poor chart, and today it is overvalued with a repaired one. Second-quarter results land on August 27. There is no case for pre-positioning eleven days before the print that settles the argument.

INVESTMENT SCORE

62 / 100

unchanged from 62

1. The Accumulation Zone Was Reached, and It Is Gone

The July 26 report is unusual in this coverage for having been tested almost immediately. It set an ideal accumulation range of \$158–178, a first-tranche trigger at \$180 on a hold of the 100-day average, a second tranche at \$160, a stop at \$148, and targets at \$250 and \$300, while stating plainly that no position was recommended at \$194.23. Three sessions later, on July 29, the stock closed at \$163.40 having traded as low as \$162.90 — inside the named range, and within three dollars of the second-tranche level. A reader following the plan would have built most of a position between roughly \$163 and \$183 during that week.

What followed was a 35.9% advance in eleven trading sessions to \$222.02. The proximate cause is identifiable and is not simply drift. On August 4 Marvell used the Flash Memory Summit to launch a block of new data-centre products: Bravera SC6 SSD controllers, Structera X CXL memory expansion, and a Photonic Fabric optical shared-memory solution aimed squarely at the memory-bandwidth and capacity bottleneck in AI training clusters. The shares rose 12.8% that day and around 14% across the announcement window, on 33.9 million shares, the heaviest volume since the June unwind. Two smaller items reinforced it: a reported FCC move to restrict new Chinese optical-transceiver imports, which over time redirects DSP demand toward non-Chinese suppliers, and a \$250 million, three-year investment to roughly double Marvell's Bangalore and Hyderabad engineering headcount.

This matters more than a typical product announcement, because it lands on the half of Marvell that the July report identified as the defensible half. Optical DSP, co-packaged optics, CXL memory expansion and interconnect are the merchant businesses that carry above-average gross margin and a broad customer base, as distinct from the programme-based custom ASIC work where the hyperscaler owns the architecture and holds pricing leverage. A product cycle that broadens the merchant franchise is exactly the development that would justify a better competitive score, and it gets one below. It is also, so far, a set of launches rather than a set of revenues.

2. The Fortnight in Events

Date	Event	Read
Jul 27-29	Stock falls to \$163.40, intraday low \$162.90, on continued index-unwind selling	The July report's \$158-178 accumulation zone was entered. The plan worked as written.
Aug 4	FMS 2026 launches: Bravera SC6 SSD controllers, Structera X CXL memory expansion, Photonic Fabric optical shared memory	The material event. +12.8% on 33.9M shares. Strengthens the merchant, higher-margin side of the business.
Early Aug	Reported FCC move to restrict new Chinese optical-transceiver imports	Near-term risk to DSP shipments into Chinese module makers; over time a share tailwind toward non-Chinese suppliers.
Early Aug	\$250m, three-year India investment; Bangalore and Hyderabad headcount roughly doubling	Capacity and cost positioning for the custom silicon roadmap. Immaterial to the near-term model.
Aug 11	Wells Fargo maintains Buy, target \$240	Above the market but only 8% above it.
Aug 13	Goldman Sachs raises target to \$195 from \$180, maintains Neutral	The most instructive datapoint in the fortnight: a raised target that still sits 12.2% below the share price.
Aug 10-14	Options volume runs 90k to 210k contracts a day with open interest climbing above 1.7 million	Positioning is building into the print rather than after it. Consistent with a 7.7% average true range.
Aug 27	Q2 FY2027 results (upcoming). Investor Day follows on October 6	The gross-margin and Tier 1 XPU questions the July report posed are answered in eleven days.

3. Do the Published Levels Still Hold?

The levels hold; the price has left them behind. The accumulation range of \$158–178 is deliberately not being raised, and the reason is worth stating because raising it would be the easiest error available here. That range was not derived from a moving average that happens to have risen. It was derived from a discount to fair value, and the fair value has moved from \$196 to \$202 — a 3% change — while the share price has moved 14.3%. Lifting a buy zone by fourteen percent to keep pace with a rally, on a business whose numbers have not been updated since May, is anchoring on the quote rather than analysing it.

The consequence is uncomfortable but honest: at \$222.02 the published plan has nothing to offer. The first target is 12.6% away and the stop is 33.3% below, a ratio of 0.38 to one, against the 2.8 to one the plan was designed to deliver from a \$175 average entry. Goldman Sachs raising its target to \$195 and keeping a Neutral rating is the same observation from a different desk: the price is now above where a cautious analyst thinks the equity belongs.

Level	Published Jul 26	Status at \$222.02	Reset to	Why
Ideal accumulation range	\$158-178	Reached July 29 at \$162.90 intraday; now 20-29% below	\$158-178 (unchanged)	Anchored to a discount to fair value, not to a moving average. Fair value moved 3%; the price moved 14.3%.
First tranche trigger	\$180 on a hold of the 100-day	Triggered in the July 28-30 window	\$185 on a retest of the 100-day (now \$197.83)	The only level that moves, because it was explicitly defined against the 100-day average, which has risen.
Second tranche	\$160	Within \$3 of the July 29 low	\$160 (unchanged)	Unchanged. Only if the fundamentals are unchanged when it trades.
Stop loss	\$148	33.3% below	\$148 (unchanged)	Still beneath the pre-June consolidation base. The invalidation logic has not changed.
Take-profit 1	\$250	+12.6% away	\$250 (held)	Sits inside the roughly \$244-257 consensus band. Unchanged.

Level	Published Jul 26	Status at \$222.02	Reset to	Why
Take-profit 2	\$300	+35.1% away	\$300 (held)	Bull-case fair value near the June high of \$329.88.
Fair value	\$196 (+1%)	\$202, now 9.1% below the price	\$202	Bull weighting raised from 25% to 28% on the FMS product cycle; bear cut to 22%. The scenario values themselves are unchanged.

These parameters remain conditional and do not constitute a current buy instruction. No position is recommended at \$222.02.

4. Valuation

Every valuation figure has worsened by the same 14.3% the share price rose, because no financial disclosure has been issued since the first-quarter results in May. Enterprise value is now near \$205 billion against \$179 billion in July, which is 17.8 times guided fiscal 2027 revenue and roughly 56 times estimated fiscal 2027 non-GAAP earnings. On the fiscal 2028 target the multiple is about 39 times. GAAP remains near-meaningless: stock-based compensation ran at 8.6% of revenue in the first quarter and acquired-intangible amortisation of \$225.2 million consumes nearly all reported profit. Free cash flow yield remains below 1%, and goodwill and acquired intangibles still equal roughly 90% of book value after the Celestial AI transaction.

The comparison the July report drew with Broadcom has grown wider rather than narrower. A competitor holding roughly 70% of custom ASIC share, with superior margins and vastly larger free cash flow, trades near 20 to 24 times forward earnings. Marvell now trades near 56. That gap is a growth premium, and the July report's warning about growth premia stands: they are the first thing the market withdraws when capital-expenditure expectations moderate. The August rally has made the equity more dependent on that premium surviving, not less.

Method	Reading	Verdict vs \$222.02
EV / FY27 guided revenue	17.8x on ~\$11.5bn (was 15.5x)	Full even for 40% growth. The multiple expanded with no estimate change.
FY27 non-GAAP P/E	~56x (was 49x)	Demanding. Pays in full for guidance that will not be verified for four quarters.
FY28 non-GAAP P/E	~39x on the \$16.5bn target (was 34x)	The bull case's own multiple, applied to a target 18 months out.
GAAP P/E	Above 100x; quarterly GAAP EPS near \$0.04	Not a usable lens, as before.
Free cash flow yield	Below 1%	No support from cash generation at this valuation.
Base-case DCF	\$135 on 10% WACC and \$8.2bn of free cash flow by 2030	39% below the market. Reaching \$222 needs roughly \$13bn by 2030.
Peer check (Broadcom)	~20-24x forward on larger share and better margins	The discount Marvell should trade at has become a large premium.
Consensus target	~\$244-257 across the major panels; Wells Fargo \$240, Goldman Sachs \$195 Neutral	+10% to +16% implied. Goldman's raised target still sits 12.2% below the price.

5. Risk Register

Risk	Prob.	Severity	Note
Binary event risk into August 27	High	High	New and immediate. Q2 FY27 results land in eleven days with the stock 9% above fair value, a 7.7% average true range and open interest above 1.7 million contracts. This alone argues against establishing a position now.
Valuation offers no margin of safety	High	High	Escalated. In July fair value equalled the price. Today the price is 9.1% above it and 64% above the base-case DCF.

Risk	Prob.	Severity	Note
Gross margin mix shift	Med-High	High	Unchanged and unresolved. Non-GAAP gross margin drifted from 59.8% to 58.9% year on year as custom silicon, the lower-margin half, is guided to double. A break below 56% resets the earnings model.
Hyperscaler capex deceleration	Medium	High	Unchanged. Essentially all incremental growth is funded by four buyers. Deceleration compresses estimates and multiple at once.
Tier 1 XPU programme still 'line of sight'	Medium	High	Unchanged. The largest single assumption inside the \$16.5bn FY28 target has not been confirmed as contracted.
Flagship socket loss to a rival ASIC house	Low-Med	High	Unchanged. Reports continue to suggest Alchip leads on future Trainium generations.
FCC restrictions cut near-term China DSP shipments	Medium	Low-Med	New, and two-sided. Near-term volume into Chinese module makers is at risk; the medium-term share shift favours Marvell.
Realised volatility	High	Medium	Unchanged in character. ATR(14) of \$17.01 is 7.7% of the price. Position sizing is constrained by volatility, not conviction.
Balance-sheet quality	Medium	Medium	Unchanged. Goodwill and acquired intangibles equal roughly 90% of book value; net debt is a modest \$1.1bn.

6. Sentiment and Technicals

The sell side is bullish and dispersed, which is the normal condition for a stock whose value turns on a target eighteen months out. Consensus sits somewhere between \$244 and \$257 depending on the panel, with a Buy to Strong Buy skew. The two moves that actually happened in the fortnight are more informative than the average. Wells Fargo held Buy at \$240 on August 11, eight percent above the market. Goldman Sachs raised its target to \$195 from \$180 on August 13 and kept a Neutral rating, which is the unusual case of an analyst raising a number while the share price runs past it. Options activity has been heavy throughout, with 90,000 to 210,000 contracts traded daily and open interest climbing above 1.7 million into the print.

Technically the picture has genuinely improved from the July report, and this is the one score that rises for chart reasons. Marvell has reclaimed its 100-day average, now \$197.83, and trades 12.2% above it and 9.6% above the 20-day at \$202.51. MACD has closed most of the gap to its signal line, at -1.57 against -6.42 with a histogram of +4.84, which is the most constructive momentum reading since the June unwind began. RSI at 53.7 is neutral despite a 36% advance, which is itself notable. The trend is not repaired: the 50-day average sits at \$238.10 and is still falling, MACD remains below zero, and the stock is 32.7% beneath the June 18 high of \$329.88. What has happened is that the index-inclusion unwind has been absorbed and a base has formed. That is a better setup than July's and a worse price.

Indicator	Reading	Interpretation
Price vs 20-day SMA	\$222.02 vs \$202.51	Above (+9.6%). Extended short term after a 36% eleven-session move.
Price vs 50-day SMA	\$222.02 vs \$238.10	Below (-6.8%). The 50-day is still declining and remains the trend hurdle.
Price vs 100-day SMA	\$222.02 vs \$197.83	Above (+12.2%). Reclaimed, which was the July report's base-building condition.
Price vs 200-day SMA	Not computed; the retrieved series covers 100 sessions	The July report noted the stock was 51% above the 200-day at \$194.23. It is further above it now.
RSI(14)	53.7 (was below 50 in July)	Neutral. Unusually calm for the size of the advance.
MACD(12,26,9)	-1.57 / signal -6.42 / hist +4.84	Still negative but converging fast. The clearest improvement since July.

Indicator	Reading	Interpretation
ATR(14)	\$17.01 (7.7% of price)	Extreme. A 7-8% daily range is normal here and dictates position size.
Support / resistance	Support \$208, then \$197.83 (100-day), then \$162.90; resistance \$231.38, then \$238.10 (50-day), then \$250	\$162.90 is the July 29 low and the accumulation zone. \$250 is the first target and the consensus band.
Volume	20-day avg 21.9M vs 50-day 39.6M	The advance came on materially lighter volume than the June distribution. Worth noting.

Technicals are used here to set entry and stop levels only. They do not override the fundamental case.

7. Scorecard

Criterion	Score	Prev	Basis
Business Quality	7 / 10 	7	Unchanged. Genuine IP in SerDes, optical DSP and switching, but half the growth is programme-based ASIC work where the customer owns the architecture.
Financial Strength	6 / 10 	6	Unchanged. Net debt of \$1.1bn and record cash generation, against near-zero GAAP earnings and a book value that is 90% goodwill and intangibles.
Competitive Advantage	7 / 10 	6	Up one. The FMS product block broadens the merchant, higher-margin franchise into CXL memory expansion and optical shared memory, and the FCC action on Chinese transceivers points DSP share this way.
Management	7 / 10 	7	Unchanged. Murphy raises and meets targets and divests as willingly as he acquires; marked down for expensive acquisition currency and one-directional insider selling.
Growth Potential	9 / 10 	9	Unchanged. 40% guided in FY27, 45% in FY28, custom silicon above \$10bn by FY29.
Valuation	3 / 10 	4	Down one. 56x FY27 and 39x FY28 non-GAAP after a 14.3% price move with no estimate change. The probability-weighted fair value now sits 9.1% below the market.
Risk (10 = lowest risk)	4 / 10 	4	Held. Customer concentration, margin mix and a 7.7% average true range are unchanged; the added binary risk of an August 27 print is offset by an eleven-day window in which it resolves.
Technical Setup	5 / 10 	4	Up one. Reclaimed the 100-day with MACD converging, offset by a falling 50-day overhead and a MACD still below zero.
OVERALL	62 / 100	62	Unchanged, but not because nothing happened. A better competitive position and a repaired chart were paid for exactly by a worse price.

Scored 1-10, where 10 is always best, including Risk. Weighting: Business Quality 12, Financial Strength 12, Competitive Advantage 13, Management 10, Growth Potential 20, Valuation 18, Risk 10, Technical Setup 5 — unchanged from the initiation report, with growth and valuation carrying the heaviest weights because they are the two variables that decide the outcome. The previous report scored Risk on the same direction (labelled 'higher = safer'), so the 4 shown under 'Prev' is directly comparable and needed no restatement.

8. Recommendation: WATCHLIST (reaffirmed)

Parameter	Level / guidance	Change vs Jul 26
Recommended action	No position at \$222.02. Wait for the August 27 print before doing anything.	Unchanged in substance, more emphatic in timing
Ideal accumulation range	\$158-178, only if fundamentals are unchanged when it trades there	Unchanged — deliberately not raised with the price

Parameter	Level / guidance	Change vs Jul 26
First tranche trigger	\$185 on a retest and hold of the 100-day average, now \$197.83	Raised from \$180; the 100-day itself has risen
Second tranche	\$160	Unchanged
Stop loss	\$148, below the pre-June consolidation base	Unchanged
Take-profit target 1	\$250, inside the roughly \$244-257 consensus band	Unchanged
Take-profit target 2	\$300, bull-case fair value near the June high	Unchanged
Risk / reward at the current price	0.38 : 1 to target 1. From a \$175 average entry it would be 2.8 : 1.	Deteriorated from an already unattractive base
Expected return	-9.1% probability-weighted, against +0.9% in July	Turned negative
Holding horizon	12-24 months. The thesis resolves with FY28 results.	Unchanged
Position size if entered	2-3% of portfolio, constrained by a 7.7% average true range rather than by conviction	Unchanged
Portfolio allocation	4% or less across all AI semiconductor holdings in aggregate	Unchanged
Next catalysts	Q2 FY2027 results, August 27, 2026; Investor Day, October 6, 2026	The August date is now eleven days out rather than a month

9. Scenario Analysis

Scenario	Prob.	What has to happen	FY28 EPS	Multiple	Fair value
Bull	28%	Management's flagged upward bias materialises; custom more than doubles, NVLink Fusion adds sockets, 1.6T optics and the new CXL and photonic-fabric lines ramp ahead of plan. Gross margin holds at 58.5% or better.	\$6.60	45x	\$297
Base	50%	Guidance is met as issued. Custom doubles, the Tier 1 programme reaches volume, interconnect grows in line with rack bandwidth. Gross margin settles at 57.5%.	\$5.80	33x	\$191
Bear	22%	AI capital expenditure enters digestion during calendar 2027. One flagship programme slips or is re-sourced and merchant optics decelerates. Gross margin falls to 55.0%.	\$4.00	26x	\$105

The probability-weighted fair value is \$202, computed as $0.28 \times \$297$ plus $0.50 \times \$191$ plus $0.22 \times \$105$. The bull weighting has been raised from 25% to 28% and the bear cut from 25% to 22%, on the strength of the FMS product block and the regulatory shift in optical transceivers; the scenario values themselves are unchanged because no financial disclosure has been issued since May. The result is that fair value rose 3% while the share price rose 14.3%, turning a probability-weighted expected return of plus 0.9% in July into minus 9.1% today. The dispersion is the more important number: a bull case 34% above the price and a bear case 53% below it, on a security with a 7.7% daily range, is a distribution that punishes early entry far more than it punishes patience.

10. Final Verdict

The rating is unchanged at Watchlist, and the score is unchanged at 62, but neither is unchanged for the reason it was in July. Three weeks ago Marvell was a high-quality growth asset trading at fair value with a broken chart, and the argument was that fair value does not compensate for 99% realised volatility. Today it is a marginally better business, with a repaired chart, trading 9.1% above fair value. The competitive position improved by a point and the technical setup by a point, and the price took both of those points back through valuation. That is a coincidence of arithmetic, and it is worth naming rather than presenting as continuity.

What the August rally did and did not prove. It did demonstrate that the merchant franchise has a product cycle: Structera X, Photonic Fabric and Bravera SC6 address a real bottleneck, and they sit on the higher-margin, more defensible side of the business, which is the side the July report said was worth owning. It did not answer any of the three questions that decide the equity. Non-GAAP gross margin was drifting down as custom silicon doubles, and remains unmeasured since May. The Tier 1 XPU programme is still described as line of sight rather than contracted. And hyperscaler capital-expenditure trajectory is unchanged in the data and unresolved in the debate. Launching products does not settle any of those.

Why the accumulation zone is not being raised. Because it was never a technical level. It was a discount to fair value, and fair value has moved 3% while the price moved 14.3%. Raising a buy zone to chase a rally in a business whose accounts have not been updated for eleven weeks is precisely the behaviour that turns a research process into a momentum process. If the August 27 print raises the base case — gross margin at or above 58.5% with the fiscal 2028 target intact and the Tier 1 programme disclosed as contracted — then the fair value rises and the entry zone rises with it, on evidence rather than on price.

What would change the view. Upgrade to Buy on second-quarter gross margin at or above 58.5% with the fiscal 2028 target intact, combined with a price that still offers a discount to the resulting fair value; or on a retreat into \$158–178 with the fundamentals unchanged. Downgrade to Avoid on non-GAAP gross margin below 56%, confirmed loss of a flagship XPU socket, a cut to big-four capital expenditure guidance, or a break and hold below \$150. Until August 27, the correct action is the one the July report prescribed and the market briefly rewarded: keep the alerts set, and do nothing.

Sources: Alpha Vantage daily OHLCV (close of August 14, 2026) — one API call, used for both the current price and the technical series. Marvell Technology Q1 FY2027 results (Form 8-K exhibit 99.1, filed May 27, 2026) and associated guidance, carried forward from the July 26 report; no financial disclosure has been issued since. Benzinga, TradingKey, StocksToTrade and Blockonomi coverage of the August 4 Flash Memory Summit product launches, the reported FCC action on Chinese optical transceivers and the India investment. moomoo news search for the August 11 Wells Fargo reiteration at \$240, the August 13 Goldman Sachs target increase to \$195 at Neutral, and daily options volume and open interest. Public.com, StockAnalysis.com and ChartMill for the analyst consensus range. The July 26, 2026 Marvell report for the prior levels, scores, scenario values and weighting. Technical indicators were computed from the daily series rather than read from third-party summaries; the 200-day average could not be computed from a 100-session series and is not quoted. No earnings call took place in this period, so no transcript applies; the next is August 27, 2026. Figures are indicative snapshots as of the report date and will move.

Disclaimer: Independent educational analysis, not personalised investment advice. The author is not a licensed financial advisor and holds no position disclosed here. Forward estimates are uncertain and may prove materially wrong. Do your own due diligence before acting.